MABT is a pharmaceutical company focused on the development and commercialization of novel therapeutic approaches and AI-enabled technologies. Our scientific and medical focus is on oncology and CNS disorders, targeting diseases such as ovarian, breast, lung, and adult and pediatric brain cancers, viral encephalitis, Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS).
DOYLESTOWN, Pa., Nov. 17, 2026 /PRNewswire-PRWeb/ -- MABT today announced that Professor Srinivasan Madhusudan has joined its Scientific Advisory Board (SAB). Professor Madhusudan brings extensive expertise in translational cancer research, DNA damage response (DDR) biology, and the development of precision medicine strategies targeting DNA repair vulnerabilities in cancer. He is Professor of Medical Oncology at the University of Nottingham, UK, and Director of the Naaz-Coker Ovarian Cancer Research Centre in the Biodiscovery Institute.
"We are delighted to welcome Professor Madhusudan to MABT's Scientific Advisory Board," said David Horn, Chief Executive Officer of MABT. "His ability to connect DNA repair biology with the clinical challenges of treating cancer brings an invaluable perspective to our team. His expertise in translational medicine, therapeutic resistance, and biomarker-guided treatment strategies will help us sharpen our scientific priorities and build a strong foundation for translating promising research into meaningful advances for patients."
Professor Madhusudan's research integrates laboratory investigation of DNA damage signaling and repair with the identification of biomarkers, therapeutic targets, and personalized treatment strategies. His clinical research expertise spans breast, ovarian, and upper gastrointestinal cancers, complemented by substantial experience in cancer clinical trials and previous leadership of the Cancer Clinical Trials Unit at Nottingham University Hospitals and NHS Cancer Genomics.
His published work encompasses base excision repair, PARP biology, DNA damage response signaling, and synthetic lethality—approaches that exploit specific DNA repair vulnerabilities in cancer cells. His research includes studies of APE1, XRCC1 and FEN1, as well as strategies involving ATR, ATM, and other DDR targets. These investigations connect tumor biology and biomarker evaluation with opportunities to address treatment resistance and develop more precisely targeted therapies.
In his advisory role, Professor Madhusudan is expected to provide scientific and translational guidance, with an emphasis on connecting target biology, preclinical evidence, and biomarker strategies to clinically relevant development questions.
Professor Madhusudan trained in medical oncology at Oxford and completed his Ph.D. at the Weatherall Institute of Molecular Medicine as a Cancer Research UK Clinical Research Fellow. His contributions to translational cancer research were recognized with the Royal College of Physicians' Lady Estelle Wolfson Lectureship in Translational Medicine in 2019.
About MABT:
We are a pharmaceutical company focused on the development and commercialization of novel therapeutic approaches and AI-enabled technologies. Our scientific and medical focus is on oncology and CNS disorders, targeting diseases such as ovarian, breast, lung, and adult and pediatric brain cancers, viral encephalitis, Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS).
Media Contact
David Horn, M.D., MABT, 1 2156104838, [email protected], MABT.us
SOURCE MABT


Share this article